Harrow, Inc. — Form 8-K Summary
Reporting context: The 8-K reports the completion on October 1, 2026 of Harrow’s acquisition from Viatris of TYRVAYA rights and related assets outside Japan. The filing is dated October 5, 2026. TYRVAYA is a varenicline nasal spray indicated for signs and symptoms of dry eye disease.
Transaction and financial terms
- Harrow paid Viatris $30.0 million in cash at closing, funded with cash on hand.
- Harrow may owe up to $70.0 million in contingent milestone payments, tied to specified TYRVAYA net-sales thresholds measured over 12-month periods ending on or before December 31, 2029.
- The acquired assets include the related regulatory approvals, intellectual property, technology, inventory and certain contracts. Harrow also assumed specified related liabilities.
- Viatris retained TYRVAYA commercialization rights in Japan. Under a side letter, Viatris is obligated to pay Harrow tiered royalties on annual Japanese net sales; the parties agreed to negotiate a separate collaboration or similar agreement for Japan.
The filing provides no company-level revenue, profit, cash-flow, margin, debt or liquidity figures, and no quantified forecast for the acquired product.
Change from the prior agreement
The parties amended and restated the purchase agreement on October 1. Compared with the August 3, 2026 agreement, Japan rights were excluded from the acquired assets and the post-closing net-working-capital purchase-price adjustment was eliminated. The cash consideration was consequently fixed at $30.0 million. The filing says the contingent milestones and other principal terms were not materially changed.
Outlook, risks and contingencies
Milestone payments depend on achieving the specified sales thresholds. The contemplated Japan collaboration has not yet been reported as negotiated or executed, and royalty receipts depend on Japanese sales. Harrow cautions that forward-looking outcomes may differ materially and refers investors to its other SEC filings for risk factors. The filing states that Harrow will file the purchase agreement as an exhibit to its Form 10-Q for the quarter ended September 30, 2026.
Important facts for investors to verify
- The full purchase agreement, including milestone thresholds, measurement mechanics and assumed liabilities, when filed with the Form 10-Q.
- Whether the Japan collaboration agreement is completed and its terms, including the royalty tiers and allocation of responsibilities.
- TYRVAYA sales performance and whether sales trigger any of the up-to-$70.0 million in milestone payments.
- The acquisition’s impact on Harrow’s subsequent financial results and cash position.